AstraZeneca's AZD7442 Trial Showed Reduced Risk of Severe Covid-19

 AstraZeneca PLC said Monday that high-level results from the AZD7442 long-acting antibody's Phase 3 trial showed a statistically significant reduction in the risk of developing severe Covid-19 or death.

The U.K. pharmaceutical company said the trial met its primary endpoint, and that AZD7442 was the only long-acting antibody combination shown to both prevent and treat Covid-19.

"These important results for AZD7442... add to the growing body of evidence for use of this therapy in both prevention and treatment of Covid-19. An early intervention with our antibody can give a significant reduction in progression to severe disease, with continued protection for more than six months," the company said.

https://www.marketscreener.com/quote/stock/ASTRAZENECA-PLC-4000930/news/AstraZeneca-s-AZD7442-Trial-Showed-Reduced-Risk-of-Developing-Severe-Covid-19-36648765/